Vertex Pharmaceuticals Incorporated, (VRTX), a manufacturer of small molecule drugs for patients with serious diseases, Tuesday announced a new data from a viral kinetic study of the uridine nucleotide analogue, ALS-2200 or VX-135 in development for the treatment of Hepatitis C.
There was a reduction in hepatitis C virus or HCV RNA after seven days of dosing with 200 mg once daily in treatment- naïve people with genotype 1 chronic HCV infection and compensated cirrhosis. Among treatment-naïve people with genotypes 3 or 4 chronic HCV infection, there was a median 4.65 log10 reduction in HCV RNA after seven days of dosing with 200 mg once daily. Prior to a protocol amendment, one treatment-naïve person with genotype 2 HCV infection received 100 mg once daily for seven days, and had a 5.04 log10 reduction in HCV RNA after seven days of dosing. ALS-2200 was well-tolerated in this study, there were no serious adverse events and no patients discontinued due to adverse events. These were performed following a non-exclusive agreement with Bristol-Myers Squibb Company. According to the agreement, Vertex plans to conduct two Phase 2 studies of the combination, including an initial study in treatment-naïve people with genotype 1 HCV infection planned for the second quarter of this fiscal. Vertex plans to begin a subsequent study in treatment-naïve people infected with genotype 1, 2 or 3 HCV, including those with cirrhosis, in the second half of 2013, pending data from the initial study.
VX-135 is a uridine nucleotide analogue pro-drug designed to inhibit the replication of the hepatitis C virus by acting on the NS5B polymerase. Hepatitis C is a serious liver disease caused by the hepatitis C virus, which is spread through direct contact with the blood of infected people and ultimately affects the liver.
Currently, Vertex is trading up $2.02 or 2.46 percent at $84.35 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.